Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

by Clinical Neuropsychologist | Saturday, August 3, 2024 | Dementia

Abstract INTRODUCTION We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS We...

Are lecanemab and donanemab disease‐modifying therapies?

by Clinical Neuropsychologist | Saturday, August 3, 2024 | Dementia

Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Timothy Daly, Kasper P. Kepp, Bruno P. Imbimbo | August 3, 2024...

Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism

by Clinical Neuropsychologist | Friday, August 2, 2024 | Dementia

Abstract INTRODUCTION Triggering receptor expressed on myeloid cells 2 (TREM2) agonists are being clinically evaluated as disease-modifying therapeutics for Alzheimer’s disease. Clinically translatable pharmacodynamic (PD) biomarkers are needed to confirm drug...

Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time

by Clinical Neuropsychologist | Thursday, August 1, 2024 | Dementia

Abstract INTRODUCTION We disclosed amyloid positron emission tomography (PET) results in individuals with subjective cognitive decline (SCD) and studied patient experiences and outcomes over a 6-month period. METHODS Fifty-seven participants from the Subjective...

Characterization of white matter hyperintensities in Down syndrome

by Clinical Neuropsychologist | Thursday, August 1, 2024 | Dementia

Abstract INTRODUCTION In Down syndrome (DS), white matter hyperintensities (WMHs) are highly prevalent, yet their topography and association with sociodemographic data and Alzheimer’s disease (AD) biomarkers remain largely unexplored. METHODS In 261 DS adults...

Data sharing as the foundation of discovery: ADNI and breakthroughs in Alzheimer’s disease

by Clinical Neuropsychologist | Tuesday, July 30, 2024 | Dementia

Abstract The COVID pandemic has shown that when the research community comes together, we can conquer the most complex biomedical challenges. Collaboration and teamwork among federal agencies, private organizations, and researchers have been crucial in the development...